Compare LEU & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | XERS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1998 | 2021 |
| Metric | LEU | XERS |
|---|---|---|
| Price | $89.65 | $16.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | ★ $180.00 | $17.29 |
| AVG Volume (30 Days) | 730.7K | ★ 2.9M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $193,000,000.00 | $49,590,000.00 |
| Revenue This Year | $6.14 | $37.58 |
| Revenue Next Year | $7.34 | $31.16 |
| P/E Ratio | $35.66 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $84.86 | $5.25 |
| 52 Week High | $345.60 | $17.28 |
| Indicator | LEU | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 78.36 |
| Support Level | $84.86 | $5.90 |
| Resistance Level | $117.45 | N/A |
| Average True Range (ATR) | 8.44 | 0.73 |
| MACD | 0.25 | 0.26 |
| Stochastic Oscillator | 17.38 | 88.75 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.